<?xml version="1.0" encoding="UTF-8"?>
<p>There is a recombinant vaccine, HEV 239, which is approved for use in China in those aged 16â€“65 years who are not pregnant [
 <xref rid="pntd.0006807.ref023" ref-type="bibr">23</xref>]. It is produced with a genotype 1 isolate and efficacy against both genotypes 1 and 4 has been established in non-human primates. The vaccine has been demonstrated to have &gt;90% efficacy with a three dose schedule (0, 1 and 6 months) based on a clinical trial involving 109,959 people at risk of HEV infection in an endemic setting, primarily with genotype 4 [
 <xref rid="pntd.0006807.ref023" ref-type="bibr">23</xref>]. Preliminary observations suggest the vaccine is also safe and effective in pregnant women [
 <xref rid="pntd.0006807.ref024" ref-type="bibr">24</xref>]. Clinical trial data are lacking for those aged &lt;16 or &gt;65 years, in areas where genotypes 1 and 2 dominate, and in outbreak settings.
</p>
